Download PDF
Diabetes aktuell 2019; 17(07): 272-279
DOI: 10.1055/a-1031-2237
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Hypoglykämien bei Diabetes mellitus: häufig und gefährlich

Prävention und Therapie
Andreas Holstein
1   Medizinische Klinik I, Klinikum Lippe-Detmold
,
David J.F. Holstein
2   Integriertes Forschungs- und Behandlungszentrum AdipositasErkrankungen, Universität Leipzig
› Author Affiliations
Further Information

Publication History

Publication Date:
26 November 2019 (online)

Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Schwere Hypoglykämien führen häufig zu Verletzungen und sind mit einer mehr als 2-fach erhöhten kardiovaskulären Mortalität und Morbidität assoziiert. Hauptrisikofaktoren für Hypoglykämien bei Typ-1-Diabetes sind Störungen der Hypoglykämie-Wahrnehmung bzw. rekurrente Hypoglykämien, während bei Typ-2-Diabetes komplexe geriatrische Multimorbidität und kognitive Einschränkungen dominieren. Individuelle (Re-)Schulungen der Patienten bilden die Grundlage der Prävention. Therapieziele sollten unter Wertung des Patientenwunsches, der Komorbiditäten, des Hypoglykämierisikos, der Lebenserwartung u.a. individuell festgelegt werden. Bei Typ-2-Diabetes und Hypoglykämie-Vulnerabilität sind Antidiabetika ohne intrinsisches Hypoglykämierisiko (DPP-4-Hemmer, GLP-1-Analoga, SGLT-2-Hemmer) in der Zweitlinien-Therapie nach Metformin zu bevorzugen. Moderne CGM-Technologien tragen dazu bei, insbesondere gefährliche nächtliche Hypoglykämien zu reduzieren und die Hypoglykämie-Wahrnehmung zu verbessern. Auch CSII und wahrscheinlich der Einsatz moderner Basalinsulinanaloga senken das Hypoglykämierisiko bei Typ-1- bzw. Typ-2-Diabetes. Die simultane Transplantation von Pankreas und Niere, die isolierte Pankreastransplantation und Inseltransplantation führen nicht nur zur (temporären) Insulinunabhängigkeit, sondern vermeiden auch Hypoglykämien. Die primäre Therapie bei bewusstseinsgestörten Patienten mit schwerer Hypoglykämie besteht in der streng intravenösen Gabe von 50 ml 40 %iger Glukose als Bolus. Alternativ kann die Gabe von 1 mg Glukagon intramuskulär erfolgen. Ältere komorbide oder verletzte Diabetespatienten, Sulfonylharnstoff-Hypoglykämien und Hypoglykämien unter Alkoholkonsum oder Analgetika-/Sedativa-Medikation bedürfen obligat der stationären Überwachung.

 

  • Literatur

  • 1 Marchesini G, Veronese G, Forlani G. et al The management of severe hypoglycemia by the emergency system: the HYPOTHESIS study. Nutr Metab Cardiovasc Dis 2014; 24: 1181-1188 doi:10.1016/j.numecd.2014.05.012
    CrossrefPubMedGoogle Scholar
  • 2 Goto A, Arah OA, Goto M. et al Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 2013; 347: f4533 doi:10.1136/bmj.f4533
    CrossrefPubMedGoogle Scholar
  • 3 Zinman B, Marso SP, Christiansen E. et al Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. Diabetes Care 2018; 41: 1783-1791 doi:10.2337/dc17-2677
    CrossrefPubMedGoogle Scholar
  • 4 Standl E, Stevens SR, Armstrong PW. et al Increased risk of severe hypoglycemic events before and after cardiovascular outcomes in TECOS suggests an at-risk type 2 diabetes frail patient phenotype. Diabetes Care 2018; 41: 596-603 doi:10.2337/dc17-1778
    CrossrefPubMedGoogle Scholar
  • 5 American Diabetes Association. Glycemic Targets. Diabetes Care 2017; 40 (Suppl. 01) S48-S56 doi:10.2337/dc17-S009
    CrossrefPubMedGoogle Scholar
  • 6 International Hypoglycemia Study Group Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2017; 40: 155-157 doi:10.2337/dc16-2215
    CrossrefPubMedGoogle Scholar
  • 7 Seaquist ER, Anderson J, Childs B. et al Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013; 36: 1384-1395 doi:10.2337/dc12-2480
    CrossrefPubMedGoogle Scholar
  • 8 UK Hypoglycaemia Study Group Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007; 50: 1140-1147 doi:10.1007/s00125-007-0599-y
    CrossrefPubMedGoogle Scholar
  • 9 Wright AD, Cull CA, Mcleod KM. et al Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complicat 2006; 20: 395-401 doi:10.1016/j.jdiacomp.2005.08.010
    CrossrefPubMedGoogle Scholar
  • 10 DCCT Research Group Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 1991; 90: 450-459
    CrossrefPubMedGoogle Scholar
  • 11 Holstein A, Patzer OM, Machalke K. et al Substantial increase in incidence of severe hypoglycemia between 1997-2000 and 2007-2010: a German longitudinal population-based study. Diabetes Care 2012; 35: 972-975 doi:10.2337/dc11-1470
    CrossrefPubMedGoogle Scholar
  • 12 Müller N, Lehmann T, Gerste B. et al Increase in the incidence of severe hypoglycaemia in people with Type 2 diabetes in spite of new drugs: analysis based on health insurance data from Germany. Diabet Med 2017; 34: 1212-1218 doi:10.1111/dme.13397
    CrossrefPubMedGoogle Scholar
  • 13 Zhong VW, Juhaeri J, Cole SR. et al Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study. Diabetes Care 2017; 40: 1651-1660 doi:10.2337/dc16-2680
    CrossrefPubMedGoogle Scholar
  • 14 Wang H, Donnan PT, Leese CJ. et al Temporal changes in frequency of severe hypoglycemia treated by emergency medical services in types 1 and 2 diabetes: a population-based data-linkage cohort study. Clin Diabetes Endocrinol 2017; 3: 7 doi: 10.1186/s40842-017-0045-0
    CrossrefPubMedGoogle Scholar
  • 15 Lipska KJ, Yao X, Herrin J. et al Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013. Diabetes Care 2017; 40: 468-475 doi:10.2337/dc16-0985
    CrossrefPubMedGoogle Scholar
  • 16 Lee AK, Lee CJ, Huang ES. et al Risk factors for severe hypoglycemia in black and white adults with diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 2017; 40: 1661-1667 doi:10.2337/dc17-0819
    CrossrefPubMedGoogle Scholar
  • 17 Pramming S, Thorsteinsson B, Bendtson I. et al Symptomatic hypoglycaemia in 411 type 1 diabetic patients. Diab Med 1991; 8: 217-222 doi:10.1111/j.1464-5491.1991.tb01575.x
    CrossrefPubMedGoogle Scholar
  • 18 Pedersen-Bjergaard U, Pramming S, Heller SR. et al Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev 2004; 20: 479-486 doi:10.1002/dmrr.482
    CrossrefPubMedGoogle Scholar
  • 19 Wohland T, Holstein JD, Patzer OM. et al New risk and protective factors for severe hypoglycaemia in people with type 1 diabetes. Nutr Metab Cardiovasc Dis 2017; 27: 407-414 doi:10.1016/j.numecd.2016.12.006
    CrossrefPubMedGoogle Scholar
  • 20 Holstein A, Wohland T, Patzer OM. et al Accumulation of severe hypoglycemia at weekends and in warm seasons in patients with type 1 diabetes but not with type 2 diabetes. J Diabetes Complications 2016; 30: 1308-1314 doi:10.1016/j.jdiacomp.2016.05.026
    CrossrefPubMedGoogle Scholar
  • 21 Lipska KJ, Warton EM, Huang ES. et al HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. Diabetes Care 2013; 36: 3535-3542 doi:10.2337/dc13-0610
    CrossrefPubMedGoogle Scholar
  • 22 Davies MJ, D’Alessio DA, Fradkin J. et al Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41: 2669-2701 doi:10.2337/dci18-0033
    CrossrefPubMedGoogle Scholar
  • 23 Deutsche Diabetes Gesellschaft S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter. 2. Aufl 2018 AWMF-Registernummer: 057-017. Im Internet: www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/2018/057_017_LL_Alter_Gesamtdokument_20180713.pdf Stand: 29.10.2019
    PubMedGoogle Scholar
  • 24 Sämann A, Mühlhauser I, Bender R, et al.. et al Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study. Diabetologia 2005; 48: 1965-1970 doi:10.1007/s00125-005-1905-1
    CrossrefPubMedGoogle Scholar
  • 25 Iqbal A, Heller SR. The role of structured education in the management of hypoglycaemia. Diabetologia 2018; 61: 751-760 doi:10.1007/s00125-017-4334-z
    CrossrefPubMedGoogle Scholar
  • 26 Little SA, Speight J, Leelarathna L. et al Sustained Reduction in Severe Hypoglycemia in Adults With Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia: Two-Year Follow-up in the HypoCOMPaSS Randomized Clinical Trial. Diabetes Care 2018; 41: 1600-1607 doi:10.2337/dc17-2682
    PubMedGoogle Scholar
  • 27 Leiter LA, Boras D, Woo VC. et al Dosing irregularities and self-treated hypoglycemia in Type 2 diabetes: results from the Canadian cohort of an international survey of patients and healthcare professionals. Can J Diabetes 2014; 38: 38-44 doi:10.1016/j.jcjd.2013.08.270
    CrossrefPubMedGoogle Scholar
  • 28 Kern W, Holstein A, Moenninghoff C. et al Self-reported Hypoglycaemic Events in 2 430 Patients with Insulin-treated Diabetes in the German Sub-population of the HAT Study. Exp Clin Endocrinol Diabetes 2017; 125: 592-597 doi:10.1055/s-0043-112350
    PubMedGoogle Scholar
  • 29 Bergenstal RM, Tamborlane WV, Ahmann A. et al Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010; 363: 311-320 doi:10.1056/NEJMoa1002853
    CrossrefPubMedGoogle Scholar
  • 30 Bergenstal RM, Klonoff DC, Garg SK. et al Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013; 369: 224-232 doi:10.1056/NEJMoa1303576
    CrossrefPubMedGoogle Scholar
  • 31 Martin CT, Criego AB, Carlson AL. et al Advanced Technology in the Management of Diabetes: Which ComesFirst—Continuous Glucose Monitor or Insulin Pump?. Curr Diab Rep 2019; 19: 50 doi:10.1007/s11892-019-1177-7
    CrossrefPubMedGoogle Scholar
  • 32 Ly TT, Nicholas JA, Retterath A. et al Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized controlled trial. JAMA 2013; 310: 1240-1247
    CrossrefPubMedGoogle Scholar
  • 33 Van Beers CA, DeVries JH, Kleijer SJ. et al Continuous Glucose Monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomized, open-label, crossover trial. Lancet Diabetes, Endocrinol 2016; 4: 893-902 doi:10.1001/jama.2013.277818
    CrossrefPubMedGoogle Scholar
  • 34 Heinemann L, Freckmann G, Ehrmann D. et al Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicenter, randomized controlled trial. Lancet 2018; 391: 1367-1377 doi:10.1016/S0140-6736(18)30297-6
    CrossrefPubMedGoogle Scholar
  • 35 Bolinder J, Antuna R, Geehoed-Duijvestin P. et al Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes : a multicentre, non-masked, randomized controlled trial. Lancet 2016; 388: 2254-2263 doi:10.1016/S0140-6736(16)31535-5
    CrossrefPubMedGoogle Scholar
  • 36 Haak T, Hanaire H, Ajjan R. et al Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label, randomized, controlled trial. Diabetes Ther 2017; 8: 55-73 doi: 10.1007/s13300-016-0223-6
    CrossrefPubMedGoogle Scholar
  • 37 Tyndall V, Stimson RH, Zammitt NN. et al Marked improvement in HbA1c following commencement of flash glucose monitoring in people with type 1 diabetes. Diabetologia 2019; 62: 1349-1356 doi:10.1007/s00125-019-4894-1
    CrossrefPubMedGoogle Scholar
  • 38 Graveling AJ, Frier BM. The risks of nocturnal hypoglycaemia in insulin-treated diabetes. Diabetes Res Clin Pract 2017; 133: 30-39 doi:10.1016/j.diabres.2017.08.012
    CrossrefPubMedGoogle Scholar
  • 39 Frier BM, Ratzki-Leewing A, Harris SB. Reporting of hypoglycaemia in clinical trials of basal insulins: a need for Consensus. Diabetes Metab Obes 2019; 21: 1529-1542 doi:10.1111/dom.13732
    Google Scholar
  • 40 Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009; 11: 372-378 doi:10.1111/j.1463-1326.2008.00976.x
    CrossrefPubMedGoogle Scholar
  • 41 Singh SR, Ahmad F, Lal A. et al Efficacy and safety of insulin analogues for the management of diabetes mellitus: A meta-analysis. CMAJ 2009; 180: 385-397 doi:10.1503/cmaj.081041
    CrossrefPubMedGoogle Scholar
  • 42 Heller S, Buse J, Fisher M. et al Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1489-1497 doi:10.1016/S0140-6736(12)60204-9
    CrossrefPubMedGoogle Scholar
  • 43 Bode BW, Buse JB, Fisher M. et al Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med 2013; 30: 1293-1297 doi:10.1111/dme
    CrossrefPubMedGoogle Scholar
  • 44 Ratner RE, Gough SCL, Mathieu C. et al Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013; 15: 175-184 doi:10.1111/dom.12032
    CrossrefPubMedGoogle Scholar
  • 45 Lane W, Bailey TS, Gerety G. et al Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA 2017; 318: 33-44 doi:10.1001/jama.2017.7115
    CrossrefPubMedGoogle Scholar
  • 46 Agesen RM, Alibegovic AC, Andersen HU. et al The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in subjects with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design. BMC Endocr Disord 2019; 19: 78 doi:10.1186/s12902-019-0408-x
    CrossrefPubMedGoogle Scholar
  • 47 Marso SP, McGuire GK, Zinman B. et al Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. NEJM 2017; 377: 723-732 doi:10.1056/NEJMoa1615692
    CrossrefPubMedGoogle Scholar
  • 48 Wysham C, Bhargava A, Chaykin L. et al Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA 2017; 318: 45-56 doi:10.1001/jama.2017.7117
    CrossrefPubMedGoogle Scholar
  • 49 Rosenstock J, Cheng A, Ritzel R. et al More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. Diabetes Care 2018; 41: 2147-2154 doi:10.2337/dc18-0559
    CrossrefPubMedGoogle Scholar
  • 50 Lombardo C, Perrone VG, Amorese G. et al Update on pancreatic transplantation on the management of diabetes. Minerva Med 2017; 108: 405-418 doi:10.23736/S0026-4806.17.05224-7
    PubMedGoogle Scholar
  • 51 Holstein A, Wunsch A. Pancreas transplantation alone in a nonuremic woman with type 1 diabetes mellitus and total unawareness of hypoglycaemia. Diabetologie 2011; 6: 329-330 doi:10.1055/s-0031-1283751
    Article in Thieme ConnectGoogle Scholar
  • 52 Lablanche S, Vantyghem MC, Kessler L. et al Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol 2018; 6: 527-537 doi:10.1016/S2213-8587(18)30078-0
    CrossrefPubMedGoogle Scholar
  • 53 Villani M, deCourten B, Zoungas S. et al Emergency treatment of hypoglycaemia: a guideline and evidence review. Diabet Med 2017; 34: 1205-1211 doi:10.1111/dme.13379
    CrossrefPubMedGoogle Scholar
  • 54 Deutsche Diabetes Gesellschaft S3-Leitlinie Therapie des Typ-1-Diabetes. 2. Aufl 2018 AWMF-Registernummer: 057-013. Im Internet: www.awmf.org/uploads/tx_szleitlinien/057-013m_S3-Therapie-Typ-1-Diabetes_2018-04.pdf Stand: 29.10.2019
    PubMedGoogle Scholar
  • 55 Rickels MR, Ruedy KJ, Foster NC. et al Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care 2016; 39: 264-270 doi:10.2337/dc15-1498
    PubMedGoogle Scholar
  • 56 Holstein A, Hammer C, Hahn M. et al Severe sulphonylurea-induced hypoglycaemia - a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opin Drug Saf 2010; 9: 675-681 doi:10.1517/14740338.2010.492777
    CrossrefPubMedGoogle Scholar
  • 57 Holstein A, Beil W, Kovacs P. CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert Opin Drug Metab Toxicol 2012; 8: 1549-1563 doi:10.1517/17425255.2012.722619
    CrossrefPubMedGoogle Scholar
  • 58 Vaccaro O, Masulli M, Nicolucci A. et al Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol 2017; 5: 887-897 doi:10.1016/S2213-8587(17)30317-0
    CrossrefPubMedGoogle Scholar
  • 59 Rosenstock J, Kahn SE, Johansen OE. et al Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes. The CAROLINA Randomized Clinical Trial. JAMA 2019; 322: 1155-1166 doi:10.1001/jama.2019.13772
    CrossrefPubMedGoogle Scholar